Accustem Sciences (ACUT) Operating Expenses (2021 - 2026)
Accustem Sciences (ACUT) posted quarterly Operating Expenses of $485883.0 for Q1 2026, up 10.33% year-over-year from $440408.0 in Q1 2025, and down 5.54% quarter-over-quarter from $514388.0 in Q4 2025.
Accustem Sciences (ACUT) Operating Expenses (2021 - 2026) Analysis & Trends
Accustem Sciences (ACUT) has reported Operating Expenses for 6 consecutive years, with $485883.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Expenses rose 10.33% year-over-year to $485883.0; the TTM figure through Mar 2026 stood at $1.8 million (up 26.97% YoY), while the FY2025 annual figure was $1.8 million, up 16.68% from the prior year.
- Operating Expenses fell to $485883.0 in Q1 2026 per ACUT's latest filing, from $514388.0 in the prior quarter.
- Across five years, Operating Expenses topped out at $1.1 million in Q2 2022 and bottomed at $246042.0 in Q4 2023.
- Historically, Operating Expenses has averaged $561421.4 across 5 years, with a median of $485883.0 in 2026.
- Annual changes were most pronounced in 2022 — Operating Expenses surged 5598.36% — and 2023, when it slumped 74.86%.
- Accustem Sciences' Operating Expenses stood at $978534.0 in 2022, then plunged by 74.86% to $246042.0 in 2023, then jumped by 51.23% to $372101.0 in 2024, then surged by 38.24% to $514388.0 in 2025, then decreased by 5.54% to $485883.0 in 2026.
- Business Quant data shows ACUT's Operating Expenses at $485883.0 in Q1 2026, $514388.0 in Q4 2025, and $399897.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.06 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -784.57 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 427.03 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 541.02 Mn |
| 10 | Accustem Sciences | 2.57 Mn | 2.56 Mn | - | 350,973.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 485,883.00 |
| Dec 31, 2025 | 514,388.00 |
| Sep 30, 2025 | 399,897.00 |
| Jun 30, 2025 | 401,403.00 |
| Mar 31, 2025 | 440,408.00 |
| Dec 31, 2024 | 372,101.00 |
| Sep 30, 2024 | 328,174.00 |
| Jun 30, 2024 | 278,225.00 |
| Mar 31, 2024 | 526,602.00 |
| Dec 31, 2023 | 246,042.00 |
| Sep 30, 2023 | 598,525.00 |
| Jun 30, 2023 | 372,756.00 |
| Mar 31, 2023 | 833,341.00 |
| Dec 31, 2022 | 978,534.00 |
| Sep 30, 2022 | 899,125.00 |
| Jun 30, 2022 | 1.08 Mn |
| Mar 31, 2022 | 790,534.00 |
| Dec 31, 2021 | 543,482.00 |
| Sep 30, 2021 | 62,722.00 |
| Jun 30, 2021 | 50,537.00 |